Treatment of men with oligoasthenozoospermia and asthenozoospermia with kallikrein.
A randomised group of 75 men with idiopathic oligoasthenozoospermia and asthenozoospermia were subjected to control study with kallikrein. Kallikrein was given to 45 men 600 units daily in a period of 3-6 months. The other group of 30 infertile men was followed during the same period of time. Percentage of motile sperm was significantly improved after 3-6 months treatment with kallikrein. Sperm count and percentage of morphologically normal sperm showed improvement but was not statistically significant. Infertile men with sperm count below 20 X 10(6)/ml had greater improvement in sperm count than men with sperm count over 20 X 10(6)/ml. This study emphasizes that kallikrein is a relatively good drug for restoring sperm motility in idiopathic oligoasthenozoospermia and asthenozoospermia.
D000328:Adult; D004341:Drug Evaluation; D005303:Fertility Agents, Male / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D009845:Oligospermia / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects
D005303:Fertility Agents, Male; D007610:Kallikreins